Top Mover
Boston Scientific Warns It Will Miss 2026 Sales and Profit Targets After Cyberattack Disrupts Shipments
Boston Scientific Corporation $BSX
$44.98-5.91%as of publication
- 5D Change
- -6.86%
- Market Cap
- $71.05B
Boston Scientific said on September 8 that a cybersecurity incident, which struck in August, has materially impaired its ability to ship products to customers and will cause the medical-technology company to fall short of its full-year 2026 sales and profit forecasts. The company warned that both third-quarter and full-year results will see a material negative impact, making it unlikely to meet the financial guidance it had previously set for the year.
Shares of BSX fell sharply, sliding roughly 2% in premarket trading and continuing to underperform peers through the regular session. The stock's decline made it one of the largest premarket movers on the day, drawing attention across major financial outlets including Barron's, Reuters, Bloomberg, and the Wall Street Journal.
Analysts noted that the WATCHMAN device franchise and the electrophysiology segment were already facing pressure heading into the second half of 2026, and the cyberattack compounds that outlook. A Nasdaq analysis published the same day flagged the weakened 2026 growth outlook but pointed to seven product launches and cost-savings initiatives as potential drivers of recovery by 2028.
© AI-generated summary is provided by Market Flux
Sources
- Seeking AlphaBoston Scientific says cyberattack will materially hit Q3, full-year results
- WsjBoston Scientific Won’t Meet Guidance Due to Cyberattack
- Yahoo FinanceBoston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack
- CnbcStocks making the biggest moves premarket: Peloton Interactive, Roivant Sciences, Boston Scientific & more
- ZerohedgePremarket movers: Mag 7 stocks are mostly lower: Nvidia +0.3%, Tesla +0.2%, Alphabet -0.7%, Apple -0.4%, Amazon -0.9%, Microsoft -0.8%, Meta Platforms -0.5% Best Buy (BBY) slips 2% after DA Davidson cut the recommendation on the consumer electronics retailer to neutral, citing the stock’s valuation following a 35% year-to-date gain. Bloom Energy (BE) rises 6% and Everpure (P) gains 2% after S&P Dow Jones Indices said the companies will join the S&P 500 Index. Boston Scientific (BSX) slips 2% after the company said that the cyber attack that recently affected operations is likely to have a material impact on third quarter and fiscal 2026 results. Herbalife (HLF) rises 7% after the maker of dietary supplements announced a $250 million share buyback. Ionis Pharmaceuticals (IONS) falls 10% and Amgen (AMGN) slumps 5% after Novartis AG said its heart medication, pelacarsen, failed in a final-stage study. Pharvaris (PHVS) soars 25% after a Phase 3 trial of its deucrictibant extended-release tablet for the prevention of hereditary angioedema attacks met its primary and secondary endpoints. Rigetti Computing (RGTI) rises 5% after the quantum computing firm signed a $100 million pact with the US Department of Commerce to accelerate superconducting quantum computing R&D. Roivant (ROIV) gains 20% after the drugmaker said a mid-stage study of its inhaled drug, mosliciguat, met its primary endpoint in the treatment for a lung disease. Sigma Lithium (SGML) drops 16% after a Brazilian court ordered the suspension of all environmental permits for an operating subsidiary of the company and the complete halt of mining activities for the firm’s Grota do Cirilo lithium project. Sweetgreen (SG) is up 5% after KeyBanc raised its recommendation on the salad restaurant chain to overweight, calling it a compelling turnaround opportunity.
- BusinessBoston Scientific says a cybersecurity incident has impacted its ability to ship its products to customers, and will cause it to miss its forecasts for the year
- Marketsday#US STOCK MARKET #PRE -MARKET BUZZ — SEPTEMBER 08, 2026 🔹 Amgen $AMGN : Held steady in early trade, providing healthcare sector stability as defensive balance sheets attract safety flows amidst broader market risk-off sentiment. 🔹 Novartis $NVS : In focus following strategic asset reshuffling, including licensing and trademark transactions to streamline core pharmaceutical portfolios. 🔹 Baidu $BIDU : Monitored as broader Chinese internet ADRs navigate mixed macroeconomic data and regional tech spending trends. 🔹 Boston Scientific $BSX : Trading steadily pre-market supported by strong institutional sentiment toward cardiovascular and medical device market share expansion.
- NasdaqBoston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead?